Sign in: Staff/Students
In our latest podcast Dr Dan Hawcutt, Senior Lecturer Paediatric Clinical Pharmacology at the University of Liverpool and an Honorary Consultant Paediatrician at Alder Hey Children’s Hospital, discusses the challenges faced when making medicines for children.
For good ethical reasons, scientists have long been reluctant to experiment on children. As a result, many of the oldest and most common medications used in paediatric medicine have not been tested on the youngest patients. This means there is very little good quality research on efficacy or proper dosage.
This concerns Dr Dan Hawcutt who wants to further what we know about the medicines we give to children to make them more effective.
To find out more you can listen to the podcast by following the links below:
Listen via Blubrry
About the podcast
Our podcasts are produced in collaboration with the University of Liverpool online programmes team, Hosted by Canadian journalist and producer Neil Morrison, we aim to bring listeners closer to some of our academic experts, authors and innovative thinkers who are affecting positive change in the world today.
Visit our podcast page to learn more.
If you would like to contact our podcast with feedback or suggestions for future recordings please e-mail firstname.lastname@example.org
You must be logged in to post a comment.
All recent news
Meet 10 Amazing #LivUniGrads
Liverpool physicists reflect on ten years since the Higgs boson discovery
New landmark £2.3m Liverpool-led clinical trial launched
Shortlist for third John McGahern Annual Book Prize announced
Short Story Competition winners announced
New £2.3m trial aims to find out whether long-term #antibiotic treatment can reduce the impact that chest infections have on children with neurological impairment: https://news.liverpool.ac.uk/2022/07/04/new-landmark-2-3m-liverpool-led-clinical-trial-launched/
Postcard: @LivuniIPH urban food research draws the crowds at #Glastonbury➡️https://bit.ly/3ug65NS
Stalling improvements in #cardiovascular disease rates could cost UK £54bn, new @PLOSONE research suggests: https://news.liverpool.ac.uk/2022/06/29/stalling-improvements-in-cardiovascular-disease-rates-since-2010-could-cost-54bn-between-2020-and-2029/